| Q40126502 | 1-Adamantylamine a simple urine marker for screening for third generation adamantyl-type synthetic cannabinoids by ultra-performance liquid chromatography tandem mass spectrometry |
| Q41745036 | A Critical Role for Immune System Response in Mediating Anti-influenza Drug Synergies Assessed by Mechanistic Modeling |
| Q70646007 | A double-blind cross-over trial of amantadine hydrochloride in Friedreich's ataxia |
| Q56675598 | Adamantane derivatives: Pharmacological and toxicological properties (review) |
| Q68850311 | Amantadine and corneal deposits |
| Q24246351 | Amantadine and rimantadine for influenza A in adults |
| Q24187883 | Amantadine and rimantadine for influenza A in children and the elderly |
| Q24203853 | Amantadine and rimantadine for influenza A in children and the elderly |
| Q24242639 | Amantadine and rimantadine for influenza A in children and the elderly |
| Q24246830 | Amantadine and rimantadine for preventing and treating influenza A in adults |
| Q40627732 | Amantadine and rimantadine prophylaxis of influenza A in nursing homes. A tolerability perspective |
| Q58066873 | Anti-influenza therapy: the emerging challenge of resistance |
| Q28547217 | Antiprotozoal Activity Profiling of Approved Drugs: A Starting Point toward Drug Repositioning |
| Q39118405 | Antiviral Treatments |
| Q30457345 | Antiviral chemotherapy and prophylaxis of viral respiratory disease |
| Q30231417 | Avian influenza virus infections in humans |
| Q33889072 | Azapropellanes with anti-influenza a virus activity. |
| Q52012754 | Behavioral effects of aminoadamantane class NMDA receptor antagonists on schedule-induced alcohol and self-administration of water in mice. |
| Q68631792 | Chromatographic methods for the bioanalysis of antiviral agents |
| Q34172068 | Clinical pharmacokinetics of amantadine hydrochloride. |
| Q43883008 | Electrophoretic behavior of adamantane derivatives possessing antiviral activity and their determination by capillary zone electrophoresis with indirect detection |
| Q39127478 | In vitro and in vivo activities of aminoadamantane and aminoalkylcyclohexane derivatives against Trypanosoma brucei |
| Q30451726 | Multiple-dose pharmacokinetics of rimantadine in elderly adults |
| Q30451294 | Oral rimantadine hydrochloride therapy of influenza A virus H3N2 subtype infection in adults |
| Q39828452 | Pharmacokinetics of a single dose of rimantadine in young adults and children |
| Q46076083 | Pharmacokinetics of amantadine in cats |
| Q37724345 | Pharmacokinetics of newer drugs in patients with renal impairment (Part I). |
| Q22305941 | Resistance to anti-influenza drugs: adamantanes and neuraminidase inhibitors |
| Q40441770 | Rimantadine: A Clinical Perspective |
| Q42288142 | Role of the viral hemagglutinin in the anti-influenza virus activity of newly synthesized polycyclic amine compounds. |
| Q35282312 | Safety and pharmacokinetics of rimantadine small-particle aerosol |
| Q34510226 | Separation methods for tricyclic antiviral drugs. |
| Q43072391 | Simultaneous determination of memantine and amantadine in human plasma as fluorescein derivatives by micellar electrokinetic chromatography with laser-induced fluorescence detection and its clinical application |
| Q28378405 | Susceptibilities to rimantadine of influenza A/H1N1 and A/H3N2 viruses isolated during the epidemics of 1988 to 1989 and 1989 to 1990 |
| Q34729069 | The onset of malignant glaucoma after prophylactic laser iridotomy |
| Q44847561 | Validation of a capillary zone electrophoresis method for determination of rimantadine hydrochloride in Rimantadin100 tablets and the method application to dissolution test monitoring |
| Q70248400 | [Rimantadine in the prevention and treatment of influenza A] |